Podcasts

Episode 48 | From Clinical Research to Leadership: A Conversation with Prof. Michael Boyer

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and his current role as CEO of Chris O’Brien Lifehouse.

Episode Summary

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and his current role as CEO of Chris O’Brien Lifehouse. They discuss his early interest in oncology, the influential mentors in his career, and the evolution of lung cancer treatment and research. Michael shares his perspectives on leadership in medical and research roles, the importance of building relationships, and the balance between industry-sponsored and cooperative group research. They also touch upon professional challenges, emotional resilience in oncology, and Michael’s vision for the future of his career and the field of oncology.

 Show Hosts

  • Prof Michael Boyer, Chief Executive Officer at Chris O’Brien Lifehouse
  • A/Prof Melissa Moore, Medical Oncologist at St Vincents Hospital and TOGA Education Chair.

Resources and Links

International Association for the Study of Lung Cancer 

Chris O’Brien Lifehouse 

Schwartz Rounds 

Conversations in Lung Cancer Research - Michael Boyer

Play Episode 48 | From Clinical Research to Leadership: A Conversation with Prof. Michael Boyer

More Podcasts

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into
In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'
Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining